Revvity ($RVTY) Stock Forecast: Up 8.1% Today

What is Revvity?

Revvity Inc. (RVTY) operates in the diagnostics and research sector, leveraging technology to offer valuable insights for scientists. Today, the stock displayed a notable uptrend, surpassing its competitors and achieving its second consecutive day of gains.

Why is Revvity going up?

RVTY stock is up 8.1% on Jun 25, 2026 14:11

• Revvity's stock surged by 5.74% today, closing at $105.63, demonstrating a strong performance compared to the overall market and indicating investor confidence in the company's growth trajectory.
• The bullish movement was influenced by a sector-wide uptick in diagnostics and research companies, reflecting a favorable shift in investor sentiment towards the industry.
• The integration of Signals AI into Revvity's platform likely played a role in driving the stock's upward trajectory, reinforcing its investment appeal and highlighting potential for revenue and earnings expansion in the future.
• Despite some concerns regarding regulatory and pricing challenges in specific markets, Revvity's strategic advancements and projected growth have captured investor attention, pushing the stock higher amid a broader market upswing.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

Hagens Berman has announced a securities class action lawsuit against Erasca, Inc. (ERAS) following a significant decline in its stock price. The lawsuit stems from allegations of patent infringement by Revolution Medicines and the death of a patient one month after receiving Erasca's ERAS-0015 treatment. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered losses are encouraged to contact Hagens Berman.

https://www.globenewswire.com/news-release/2026/06/25/3317237/32716/en/Erasca-Inc-ERAS-Faces-Securities-Class-Action-Amid-Patient-Death-Intellectual-Property-Questions-2-8-Billion-Market-Cap-Loss-Hagens-Berman.html

Revvity Jumps 6.8% Amid Sector-Wide Rally

Revvity, Inc. saw its stock surge 6.8% to $106.66 on Wednesday, as a broad rally positively impacted the diagnostics and research sector. This movement appears to be driven by a sector-wide sentiment shift, with several peers also experiencing significant gains, rather than company-specific news. Investors are advised to monitor whether this rally signifies a lasting trend or a short-term upswing.

https://news.alphastreet.com/revvity-jumps-6-8-amid-sector-wide-rally/

Revvity Inc. stock outperforms competitors on strong trading day

Shares of Revvity Inc. (RVTY) rose 5.74% on Wednesday, closing at $105.63. This performance outpaced the broader market, as the Dow Jones Industrial Average saw a slight gain and the S&P 500 Index experienced a minor decline. This marked the second consecutive day of gains for Revvity's stock.

https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-5e9a824f-d0429304d145?mod=mw_quote_news

Charles River Laboratories International Jumps 8.1% in Broad Rally

Charles River Laboratories International (CRL) saw an 8.1% surge on Wednesday, closing at $201.74, driven by a broad sector-wide rally in diagnostics and research companies. This strong performance, outpacing several peers, suggests a reassessment of value in the sector by investors, rather than a response to company-specific news. The synchronized gains among multiple comparable companies indicate renewed investor appetite for the industry, prompting questions about the sustainability of this shift.

https://news.alphastreet.com/charles-river-laboratories-international-jumps-8-1-in-broad-rally/

How Revvity’s New Signals AI-Powered R&D Platform (RVTY) Has Changed Its Investment Story

Revvity, Inc. has introduced Signals AI into its Signals One platform, aiming to transform R&D data into actionable insights for scientists using natural language. This enhancement strengthens Revvity's software-led investment narrative, emphasizing higher-margin recurring revenue and deeper customer relationships, despite ongoing concerns about regulatory and pricing pressures in China. The company's forecasts project significant revenue and earnings growth by 2029, suggesting a potential 14% upside to its current stock price.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/how-revvitys-new-signals-ai-powered-rd-platform-rvty-has-cha/amp

Trending Today

Revvity Price History

06.04.2026 - RVTY Stock was up 5.3%

• Strong Q1 2026 results were reported by Revvity, surpassing earnings expectations with 3% total company organic growth and improved operating margins, indicating positive financial performance.
• The company's decision to sell its immunodiagnostics business in China in favor of focusing on AI-powered software and operational efficiencies appears to have resonated well with investors, leading to an increase in the stock price.
• A sector-wide rally in medical instruments and supplies, accompanied by significant gains by peers like RVTY, indicates a broader institutional shift towards biomanufacturing and life sciences markets, heightening investor interest in companies like Revvity.
• Overall, Revvity's strategic decisions and strong financial performance were positively received by the market, resulting in a bullish movement in the stock price.

30.03.2026 - RVTY Stock was up 5.1%

• Revvity Inc.'s stock displayed strong bullish movement today, despite recent declines, possibly due to investors perceiving the stock as undervalued following its low point.
• The company's robust Q4 2025 financial results, surpassing expectations, likely bolstered investor confidence, contributing to the positive trajectory of the stock.
• Analysts' favorable ratings and optimistic price projections, ranging between $110 and $125, may have enhanced the overall positive sentiment surrounding Revvity Inc.'s stock.
• Recent underperformance of Revvity Inc. compared to industry peers and general market downturns might have presented a buying opportunity for investors, influencing today's bullish movement.

24.05.2026 - RVTY Stock was up 5.5%

• Revvity's launch of Signals AI to advance scientific R&D workflows has garnered positive attention and is expected to strengthen its position in the AI-powered scientific software market.
• The company's expansion into AI capabilities within its Signals One platform is seen as a strategic move to enhance how scientists interact with R&D data, potentially accelerating insights and decision-making in scientific research.
• The clear analyst consensus with Buy ratings and the perfect institutional shareholding score further contribute to investor confidence in Revvity's growth prospects, driving the bullish movement in the stock price.

11.05.2026 - RVTY Stock was down 5.1%

• The stock performed weaker than competitors and major indices, highlighting a particular weakness in Revvity's market position.
• Investors are observing the company's shift and its effects on revenue growth and margins, potentially contributing to the bearish movement.
• The decision to sell its China immunodiagnostics business aligns with the focus on high-growth areas but raises concerns about near-term growth and margins, impacting market sentiment negatively.
• Despite a strong financial position, an undervalued stock, and a solid GF Score™, the lack of insider buying activity and low growth rank may have prompted caution among investors, leading to the bearish movement.

02.05.2026 - RVTY Stock was down 5.4%

• Coverage was initiated on Revvity with a "Peer Perform" rating by Wolfe Research, expressing valuation concerns compared to historical trading patterns.
• Stifel reduced its price target for Revvity to $100 from $110, maintaining a Hold rating after surpassing analyst expectations in Q1 2026.
• Revvity underperformed on a day of market gains, suggesting internal factors influenced the bearish movement.
• The high P/E ratio and moderate GF Score™ of 74/100 raised caution among investors, possibly contributing to the downward pressure on Revvity's stock.

28.04.2026 - RVTY Stock was up 5.1%

• Revvity's stock experienced a strong bullish movement today, potentially influenced by the initiation of a new share repurchase program following its latest quarterly earnings release.
• Analyst targets and intrinsic value estimates suggest the stock is undervalued, with expectations of margin expansion from product mix shifts and cost actions driving optimism.
• The broader rally in the diagnostics and research sector, as seen with other companies, could have also positively impacted Revvity's stock price.
• Investors are closely monitoring the sector-wide sentiment to determine if the bullish movement in Revvity and its peers will be sustained or if it's a short-term trend.

25.05.2026 - RVTY Stock was up 8.1%

• Revvity's stock surged by 5.74% today, closing at $105.63, demonstrating a strong performance compared to the overall market and indicating investor confidence in the company's growth trajectory.
• The bullish movement was influenced by a sector-wide uptick in diagnostics and research companies, reflecting a favorable shift in investor sentiment towards the industry.
• The integration of Signals AI into Revvity's platform likely played a role in driving the stock's upward trajectory, reinforcing its investment appeal and highlighting potential for revenue and earnings expansion in the future.
• Despite some concerns regarding regulatory and pricing challenges in specific markets, Revvity's strategic advancements and projected growth have captured investor attention, pushing the stock higher amid a broader market upswing.

28.04.2026 - RVTY Stock was up 5.2%

• The uptick in RVTY's stock could be linked to the introduction of a new share buyback program post its latest quarterly earnings, showcasing trust in the company's capital allocation strategies.
• Analyst projections and estimates pointing towards undervaluation of the stock might have influenced positive market outlook, anticipating margin growth from shifts in product mix and cost measures.
• A neutral short-term perspective alongside a robust mid-term outlook in the price-driven evaluation may have boosted investor confidence, potentially propelling the stock's upward trend.
• In conclusion, a combination of favorable corporate advancements, indicators of undervaluation, and sentiment analysis likely fed into the positive momentum witnessed in RVTY today.

09.05.2026 - RVTY Stock was up 5.0%

• The bullish movement in Revvity's stock can be attributed to the strategic decision to divest its China immunodiagnostics business, aligning with its goal to concentrate on more lucrative sectors like life sciences and software.
• Investors seem to be responding positively to the company's shift towards higher-growth areas, potentially easing concerns about near-term growth and margin pressures.
• Analysts' optimism about Revvity's future revenue and earnings growth, coupled with the overall outperformance of the stock in a mixed trading day, likely contributed to the bullish sentiment.
• Despite facing risks from regulatory changes and a dilution adjustment, the market seems to be focusing on the company's long-term investment narrative and potential upside in the healthcare diagnostics sector.

05.04.2026 - RVTY Stock was up 5.0%

• The company disclosed its Q1 2026 financial results, reporting revenue of $711 million and surpassing analyst estimates for adjusted EPS. This strong performance likely influenced the bullish movement in the stock.
• Despite exceeding earnings projections, the stock's mixed response could be linked to the company revising down its full-year revenue and adjusted EPS guidance, causing uncertainty among investors.
• The decision to sell off its China Immunodiagnostics business might have boosted investor confidence by streamlining operations and focusing on more profitable segments.
• Management’s positive forecast for FY 2026, including projected adjusted EPS and revenues, may have boosted investor trust and contributed to the stock's bullish movement.

07.04.2026 - RVTY Stock was up 6.4%

• Revvity reported a rise in adjusted earnings and revenue for the first quarter, showcasing a strong financial start to the year.
• An analyst firm maintained a Buy rating on Revvity shares, indicating continued confidence in the company's stock performance.
• The company's strategic decision to divest its immunodiagnostics business in China to accelerate growth and invest in AI-powered platforms contributed to the positive market movement.
• Despite revenue falling short of expectations, the focus on AI investments and operational efficiencies is expected to enhance future performance and capitalize on increased demand in drug discovery, driving investor optimism.

06.04.2026 - RVTY Stock was up 7.3%

• Strong Q1 2026 results were reported by Revvity, surpassing earnings expectations. Additionally, they announced a strategic decision to divest their immunodiagnostics business in China to drive growth and enhance financials.
• The company's emphasis on investing in AI-powered software and operational efficiencies has garnered positive investor sentiment, boosting confidence in potential future performance.
• A sector-wide uptrend in medical instruments and supplies, reflected in peers like RVTY, signifies a larger institutional trend towards biomanufacturing and life sciences markets. This trend has contributed to the stock's bullish movement.